JP2020503014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503014A5 JP2020503014A5 JP2019532105A JP2019532105A JP2020503014A5 JP 2020503014 A5 JP2020503014 A5 JP 2020503014A5 JP 2019532105 A JP2019532105 A JP 2019532105A JP 2019532105 A JP2019532105 A JP 2019532105A JP 2020503014 A5 JP2020503014 A5 JP 2020503014A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- sequence set
- effector
- shmir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012636 effector Substances 0.000 claims description 132
- 108020004707 nucleic acids Proteins 0.000 claims description 122
- 102000039446 nucleic acids Human genes 0.000 claims description 122
- 150000007523 nucleic acids Chemical class 0.000 claims description 121
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 90
- 230000000295 complement effect Effects 0.000 claims description 69
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 claims description 51
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 claims description 51
- 239000013604 expression vector Substances 0.000 claims description 49
- 108020004414 DNA Proteins 0.000 claims description 24
- 239000002679 microRNA Substances 0.000 claims description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 9
- 239000004055 small Interfering RNA Substances 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 6
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 claims description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023023159A JP7431359B2 (ja) | 2016-12-14 | 2023-02-17 | 眼咽頭型筋ジストロフィー（ｏｐｍｄ）を治療するための試薬及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434312P | 2016-12-14 | 2016-12-14 | |
| US62/434,312 | 2016-12-14 | ||
| PCT/AU2017/051385 WO2018107228A1 (en) | 2016-12-14 | 2017-12-14 | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023023159A Division JP7431359B2 (ja) | 2016-12-14 | 2023-02-17 | 眼咽頭型筋ジストロフィー（ｏｐｍｄ）を治療するための試薬及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503014A JP2020503014A (ja) | 2020-01-30 |
| JP2020503014A5 true JP2020503014A5 (enExample) | 2020-12-03 |
| JP7233149B2 JP7233149B2 (ja) | 2023-03-06 |
Family
ID=62557655
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019532105A Active JP7233149B2 (ja) | 2016-12-14 | 2017-12-14 | 眼咽頭型筋ジストロフィー（ｏｐｍｄ）を治療するための試薬及びその使用 |
| JP2023023159A Active JP7431359B2 (ja) | 2016-12-14 | 2023-02-17 | 眼咽頭型筋ジストロフィー（ｏｐｍｄ）を治療するための試薬及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023023159A Active JP7431359B2 (ja) | 2016-12-14 | 2023-02-17 | 眼咽頭型筋ジストロフィー（ｏｐｍｄ）を治療するための試薬及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11142765B2 (enExample) |
| EP (1) | EP3555294A4 (enExample) |
| JP (2) | JP7233149B2 (enExample) |
| KR (2) | KR102495222B1 (enExample) |
| CN (2) | CN110382698B (enExample) |
| AU (2) | AU2017377661B2 (enExample) |
| CA (1) | CA3047154A1 (enExample) |
| IL (2) | IL267353B2 (enExample) |
| MX (2) | MX2019007110A (enExample) |
| RU (1) | RU2763319C2 (enExample) |
| WO (1) | WO2018107228A1 (enExample) |
| ZA (1) | ZA202106827B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102495222B1 (ko) | 2016-12-14 | 2023-02-09 | 베니텍 아이피 홀딩스 아이엔씨. | 안구인두근위축증 (opmd)의 치료제 및 이의 사용 |
| EP3866859A4 (en) * | 2018-10-17 | 2023-08-09 | Benitec IP Holdings Inc. | METHODS OF TREATMENT FOR OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) |
| CA3130221A1 (en) | 2019-02-28 | 2020-09-03 | Benitec IP Holdings Inc. | Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd) |
| AU2020414441A1 (en) * | 2019-12-23 | 2022-08-18 | Versameb Ag | Compositions and methods for simultaneously modulating expression of genes |
| WO2026011009A1 (en) * | 2024-07-02 | 2026-01-08 | Kate Therapeutics, Inc. | Compositions and methods for muscle disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0211111A (pt) * | 2001-07-12 | 2004-06-22 | Univ Massachusetts | Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula |
| EP1783645A1 (en) * | 2005-11-08 | 2007-05-09 | Actigenics | Methods for the identification of microRNA and their applications in research and human health |
| WO2008092935A2 (en) * | 2007-01-31 | 2008-08-07 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and/or increased abiotic stress resistance, and a method for making the same |
| DK2164967T3 (en) * | 2007-05-31 | 2015-10-19 | Univ Iowa Res Found | Reduction of off-target rna interferenstoksicitet |
| WO2010105372A1 (en) * | 2009-03-20 | 2010-09-23 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis c virus expression |
| EP2814514B1 (en) * | 2012-02-16 | 2017-09-13 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
| WO2014077693A1 (en) * | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
| WO2014107763A1 (en) * | 2013-01-08 | 2014-07-17 | Benitec Biopharma Limited | Age-related macular degeneration treatment |
| AU2017250017B2 (en) * | 2016-04-14 | 2022-12-22 | Benitec IP Holdings Inc. | Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof |
| KR102495222B1 (ko) * | 2016-12-14 | 2023-02-09 | 베니텍 아이피 홀딩스 아이엔씨. | 안구인두근위축증 (opmd)의 치료제 및 이의 사용 |
-
2017
- 2017-12-14 KR KR1020197019981A patent/KR102495222B1/ko active Active
- 2017-12-14 IL IL267353A patent/IL267353B2/en unknown
- 2017-12-14 US US16/469,992 patent/US11142765B2/en active Active
- 2017-12-14 CN CN201780086338.5A patent/CN110382698B/zh active Active
- 2017-12-14 AU AU2017377661A patent/AU2017377661B2/en active Active
- 2017-12-14 IL IL304674A patent/IL304674B2/en unknown
- 2017-12-14 KR KR1020237003441A patent/KR102667867B1/ko active Active
- 2017-12-14 JP JP2019532105A patent/JP7233149B2/ja active Active
- 2017-12-14 CN CN202410482087.4A patent/CN118421624A/zh active Pending
- 2017-12-14 EP EP17882179.9A patent/EP3555294A4/en active Pending
- 2017-12-14 CA CA3047154A patent/CA3047154A1/en active Pending
- 2017-12-14 WO PCT/AU2017/051385 patent/WO2018107228A1/en not_active Ceased
- 2017-12-14 RU RU2019121950A patent/RU2763319C2/ru active
- 2017-12-14 MX MX2019007110A patent/MX2019007110A/es unknown
-
2019
- 2019-06-14 MX MX2024003643A patent/MX2024003643A/es unknown
-
2021
- 2021-09-01 US US17/463,923 patent/US11932852B2/en active Active
- 2021-09-17 ZA ZA2021/06827A patent/ZA202106827B/en unknown
-
2023
- 2023-02-17 JP JP2023023159A patent/JP7431359B2/ja active Active
- 2023-08-28 AU AU2023222827A patent/AU2023222827B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522674A5 (enExample) | ||
| JP2021534798A5 (enExample) | ||
| JP2015523853A5 (enExample) | ||
| JP2025016451A5 (enExample) | ||
| JP2015518710A5 (enExample) | ||
| JP2022185052A5 (enExample) | ||
| JP2015519057A5 (enExample) | ||
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| JP2015518713A5 (enExample) | ||
| JP2016521556A5 (enExample) | ||
| JP2005521393A5 (enExample) | ||
| JP2018519835A5 (enExample) | ||
| JP2015523855A5 (enExample) | ||
| JP2019511216A5 (enExample) | ||
| JP2015518712A5 (enExample) | ||
| JP2010500025A5 (enExample) | ||
| JP2015518711A5 (enExample) | ||
| RU2018137677A (ru) | Модифицированная промоторная система u6 для тканеспецифической экспрессии | |
| WO2017050836A1 (en) | Antisense oligonucleotides and uses thereof | |
| AU2019234917B2 (en) | Inhibitors of micro-RNA 22 | |
| JP2022501044A5 (enExample) | ||
| JP2022522166A5 (enExample) | ||
| JP2024119830A5 (enExample) | ||
| RU2019121950A (ru) | Реагенты для лечения окулофарингеальной мышечной дистрофии (офмд) и их применение | |
| JP2021534796A5 (enExample) |